Q3 2025 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2025-11-14 · accession 0001831942-25-000023
$2.05B
Reported value
37
Positions
2025-09-30
Period end
The Brief · Commodore Capital LP · Q3 2025
AI · grounded in 13F
Commodore Capital LP closed its position in Scholar Rock Hldg Corp SRRK, reducing exposure by $51.36M. The fund established new positions in Amylyx Pharmaceuticals Inc AMLX for $55.39M and Terns Pharmaceuticals Inc 430 for $42.81M. Additionally, the fund increased its holdings in Cogent Biosciences Inc COGT by 213.69% and Soleno Therapeutics Inc SLNO by 121.31%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $331.9M | 16.2% | 3,525,000 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $121.1M | 5.91% | 1,400,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $108.4M | 5.29% | 2,700,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $104.1M | 5.08% | 7,250,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $96.1M | 4.69% | 4,692,809 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $93.9M | 4.58% | 2,338,287 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $92.9M | 4.54% | 3,096,754 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $91.3M | 4.46% | 1,350,000 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $88.7M | 4.33% | 17,000,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $78.3M | 3.82% | 3,028,335 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $69.1M | 3.37% | 2,850,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $69.1M | 3.37% | 3,200,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $68.1M | 3.32% | 1,025,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $60.3M | 2.95% | 2,418,476 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $56.0M | 2.73% | 585,000 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $55.4M | 2.70% | 4,075,478 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $47.2M | 2.30% | 3,375,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $42.8M | 2.09% | 5,700,000 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $42.5M | 2.07% | 750,000 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $38.0M | 1.86% | 3,225,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $34.9M | 1.71% | 3,780,055 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $33.7M | 1.65% | 1,753,054 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $33.3M | 1.63% | 1,988,084 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $30.3M | 1.48% | 500,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $25.6M | 1.25% | 1,000,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $24.5M | 1.20% | 7,692,300 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $23.7M | 1.16% | 1,500,000 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $12.6M | 0.62% | 1,500,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $11.5M | 0.56% | 290,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $10.9M | 0.53% | 2,357,319 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $9.6M | 0.47% | 800,000 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $8.8M | 0.43% | 4,401,500 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $8.7M | 0.43% | 5,397,488 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.9M | 0.39% | 750,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $6.1M | 0.30% | 483,000 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $5.6M | 0.27% | 1,575,000 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $5.4M | 0.26% | 450,829 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.